...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Lung cancer: Journal of the International Association for the Study of Lung Cancer >Mismatch repair system (MMR) status correlates with response and survival in non-small cell lung cancer (NSCLC) patients.
【24h】

Mismatch repair system (MMR) status correlates with response and survival in non-small cell lung cancer (NSCLC) patients.

机译：错配修复(MMR)系统状态相关非小细胞肺反应和生存癌症病人(NSCLC)。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Pre-clinical data suggested a relationship between inactivation of hMLH1 and hMSH2 and resistance to drugs like cisplatin and carboplatin, but not oxaliplatin. We then hypothesised that NSCLC showing loss of expression of the mismatch repair system (MMR), could be refractory to cisplatin-based, but not to oxaliplatin-based chemotherapy. Immunohistochemical expression of hMLH1 and hMSH2 was analysed on tumour samples from 93 advanced NSCLC, receiving chemotherapy with either cisplatin or oxaliplatin in combination with gemcitabine. Patients showing loss of hMLH1 or hMSH2 expression in > or = 50% of tumour cells were deemed MMR-negative (Group A), whereas cases with a normal hMLH1 or hMSH2 expression in > 50% of the tumour cells were defined MMR-positive (Group B). No differences in the response and progression rate were found in the whole patients population and in the gemcitabine/cisplatin group for both hMLH1 and hMSH2. In the gemcitabine/oxaliplatin group response rate was 38% and 0% (p=0.04) for patients with or without loss of hMSH2 expression. Median survival according to MMR status in Groups A and B, respectively was: 17 months versus 9 months for hMLH1 (p=0.031) and 10 months versus 9 months for hMSH2 (p=0.8330). Both the difference in response rate and in median survival observed according to MMR status seem to confirm what has been suggested by preclinical studies.
机译：临床前数据显示之间的关系失活的hMLH1 hMSH2和阻力药物如顺铂和卡铂,但不是铂。显示表达式的错配修复的损失系统(MMR),可以耐火材料oxaliplatin-based cisplatin-based,但不是化疗。hMLH1和hMSH2肿瘤样本进行了分析从93年先进的非小细胞肺癌,接受化疗与顺铂或铂结合吉西他滨。亏损hMLH1或hMSH2表达式> = 50%的肿瘤细胞被认为MMR-negative(集团),而与正常hMLH1或hMSH2病例表达式> 50%的肿瘤细胞定义MMR-positive (B组)。没有差异响应和进展率被发现整个人口和病人吉西他滨/顺铂组hMLH1和hMSH2。响应率为38%和0% (p = 0.04)患者有或没有hMSH2的损失表达式。状态在A和B组,分别是:17个月和9个月hMLH1 (p = 0.031)和10个月和9个月hMSH2 (p = 0.8330)。在反应率和平均的区别根据MMR状态似乎生存观察确认已被临床建议研究。

著录项

相似文献

  • 外文文献
  • 中文文献
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号